Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 43Breast Neoplasms 30Lymphoma 28Sarcoma 26Hodgkin Disease 24Triple Negative Breast Neoplasms 20Burkitt Lymphoma 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Follicular 16Neoplasms 15Ovarian Neoplasms 14Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, T-Cell, Peripheral 9Endometrial Neoplasms 9Neuroblastoma 7Neoplasm Metastasis 7Lymphoma, Mantle-Cell 7Liposarcoma 7Leukemia 7Fallopian Tube Neoplasms 7Recurrence 6Multiple Myeloma 6Leiomyosarcoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, B-Cell, Marginal Zone 5Leukemia, Lymphocytic, Chronic, B-Cell 5Inflammatory Breast Neoplasms 5Histiocytoma, Malignant Fibrous 5

Interventions

pembrolizumab 2lenvatinib 2Injections 2Paclitaxel 1Gemcitabine 1Doxorubicin 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Endometrial Cancer × Doxorubicin × 1 year × Clear all
NCT05481645 2026-01-09

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
71 enrolled
GynecologicSarcoma

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡